MARKHAM, ON, April 27, 2018 /CNW/ - MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced that it has entered into a memorandum of understanding (MoU) with Niagara College to foster the development of cannabis production expertise in Canada through its Graduate Certificate program in Commercial Cannabis Production – Canada's first postsecondary credential in this emerging field.

By partnering with Niagara College, MedReleaf is proud to be offering financial support for students and to be sharing its expertise to help develop the program's structure and curriculum in order to advance the development of the Canadian cannabis industry through a variety of activities that include:

Ongoing development of the Commercial Cannabis Production program and idea generation for any new Niagara College programs or educational seminars that may evolve with the cannabis industry;

Offering entrance scholarships for students who demonstrate either 1) academic excellence, or a commitment to innovation in the cannabis industry and 2) leadership in the cannabis industry by women;

Creating work integrated learning opportunities for students studying in the Commercial Cannabis Production program;

Creating graduate placement opportunities; and

Providing opportunities for applied research projects.

"Given the rapid growth in our industry, there is a need for skilled graduates trained in best practices for industrial scale cannabis production who are knowledgeable of our regulatory requirements," said Jason Fleming, Medreleaf's Vice President of Human Resources. "MedReleaf has established a reputation for being an industry leader in quality control and consistency, as well as producing award-winning cannabis. We are pleased to be working with Niagara College through their innovative graduate certificate program to help collectively elevate standards across the sector as the industry evolves."

Added Neil Closner, MedReleaf CEO, "Canada is in a great position to nurture some of the global leaders in the cannabis industry. Education, scientific research and innovative product development are all key facets to building a sustainable competitive advantage and our efforts to collaborate with academic institutions like Niagara College will lead to a stronger talent pool that ultimately results in better and more effective products for our patients and consumers."

"Strong connections to industry are the hallmark of Niagara College's programs, and this MoU with MedReleaf Corp. will help ensure that our Commercial Cannabis Production program continues to meet the current and future needs of this emerging industry, while creating opportunities for our students and graduates," said Vivian Kinnaird, Niagara College's dean of Business, Hospitality and Environment. "We're also grateful for MedReleaf's commitment to student scholarships, which will assist students who might otherwise be unable to pursue their educational goals."

About Niagara College

Niagara College offers more than 130 diploma, bachelor degree and advanced level programs; as well as more than 600 credit, vocational and general interest Part-Time Studies courses. Areas of specialization include food and wine sciences, advanced technology, media, applied health and community safety, supported by unique learning enterprises in food, wine, beer, horticulture and esthetics. For more information visit niagaracollege.ca.

About MedReleaf Corp.

Voted Top Licensed Producer at the 2017 Lift Canadian Cannabis Awards, MedReleaf is an R&D-driven company dedicated to innovation, operational excellence and the production of top-quality cannabis. Sourced from around the world and carefully cultivated in one of two state of the art ICH-GMP and ISO 9001 certified facilities in Ontario, the Company delivers a variety of premium products for the global medical market and is committed to serving the therapeutic needs of its medical patients and providing a compelling product assortment for the adult-use recreational consumer.

For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit MedReleaf.com or follow @medreleaf

SOURCE MedReleaf Corp.

For further information: Denise Riposati, Corporate Communications, [email protected], 289-317-1000 EXT 1118; Dennis Fong, Investor Relations, [email protected], 416-283-9930

Related Links

www.medreleaf.com

